Hussain Joins Northwestern; Douillard Named ESMO CMO

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MAHA HUSSAIN will join the Robert H. Lurie Comprehensive Cancer Center of Northwestern University as associate director for clinical sciences research, effective Sept. 1.

Hussain will also serve as co-director of the Lurie Cancer Center’s Genitourinary Oncology Program, along with Edward Schaeffer, chair of the Department of Urology at Northwestern University Feinberg School of Medicine. Hussain is currently Cis-Maisel Professor of Oncology, and professor of medicine and urology at the University of Michigan.

She has served in many scientific and leadership roles at the University of Michigan including associate director for clinical research and co-leader of the Prostate Cancer/GU Oncology Program at the UMComprehensive Cancer Center, as well as associate chief for clinical research in the Division of Hematology/Oncology.

Hussain’s research focuses on the development of therapeutics for prostate and bladder cancer. At Northwestern, Hussain will oversee the clinical sciences research programs and working groups, and foster interdisciplinary and inter-programmatic collaborations.

“We are thrilled to welcome Maha to the Lurie Cancer Center,” said Director Leonidas Platanias. “She is one of the world’s leading researchers in the field of prostate cancer and her presence will strengthen our clinical research efforts immensely.”

Hussain’s national scientific leadership roles include serving as co-chair of the Prostate Cancer Subcommittee/Genitourinary Cancer Committee of SWOG; as a member and chair of the integration panel of the U.S. Army Medical Research and Materiel Command Prostate Cancer Research Program; and as a member and chair of the FDA Oncology Drug Advisory Committee.

Hussain has held leadership roles within the American Society of Clinical Oncology and was recently elected to ASCO’s board of directors. She currently serves on ASCO’s Clinical Practice Guidelines Committee, as a member of the National Comprehensive Cancer Network International Committee and the Advanced Prostate Cancer Panel of the American Urological Association.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login